NASH Core Curriculum: Current Management

Unlocked slides from Stephen A. Harrison, MD, and CCO: Phase 2&3 drugs in NASH, effects on fibrosis, metabolic state, glycemic control, atherogenic risk

Stephen Harrison, MD, FACP, FAASLD, COL (ret.) USA, MC Released: July 20, 2021

Video from Clinical Care Options (CCO) and Stephen A. Harrison, MD: Emerging treatments for NASH and measuring hepatic and extrahepatic outcomes

Stephen Harrison, MD, FACP, FAASLD, COL (ret.) USA, MC Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: July 20, 2021 Expired: July 19, 2022

Where Did We Start?

Where Are We Going?

Hepatic Outcomes

Extrahepatic Outcomes

Video from CCO and Giada Sebastiani, MD: Diet, exercise, and current treatments for NASH; Mediterranean diet, intermittent fasting, GLP1-RAs and more

Giada Sebastiani, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: June 2, 2021 Expired: June 1, 2022

Lifestyle

Recommended Pharmacologic Therapies for NASH

Role of Current Diabetes Therapies in NAFLD/NASH

Expert advice on current NAFLD/NASH treatments: Mediterranean diet, vitamin E, pioglitazone, GLP-RAs, eg semaglutide. From Clinical Care Options (CCO)

Giada Sebastiani, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: June 2, 2021 Expired: June 1, 2022